COMPANY PROFILE · /freenome
F
Freenome
Freenome develops AI-powered blood tests for early cancer detection through machine learning analysis of circulating tumor DNA and proteins. The company has raised $1.4B cumulatively, targeting cancer diagnostics at the earliest disease stages.
Fresh · 5d ago
Latest valuation
—
Annual Recurring Revenue
—
Headcount
—
Funding total
$1.4B+
OVERVIEW
One of the largest healthcare AI financing recipients; pursuing FDA clearance for multi-cancer detection platform. Platform captures complex biomarker patterns using deep learning.
Status
active
Tier
master-list
Profitability
—
Pricing
enterprise
FUNDING HISTORY · 0
No funding rounds on file.
PRODUCTS · 0
No products catalogued yet. Press Refresh above to ask the research agent.
TEAM · 0 key people
No people linked.
SOURCES · 0 cited
No citations stored yet. Run the research agent to attach per-claim sources.